Glenmede Trust’s Lexicon Pharmaceuticals LXRX Stock Holding History

Glenmede Trust’s Portfolio LXRX Stock Details LXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-20,985	Closed	-$290K	–	2716
2016 Q4	$290K	Buy	+20,985	New	+$337K	﹤0.01%	1107

Other funds holding LXRX

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Glenmede Trust's LXRX Position: Q1 2017 in Review

Glenmede Trust sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2017, closing a stake of 20,985 shares — an estimated $290K sold.

Glenmede Trust first reported a position in LXRX in Q4 2016 and held it in 1 quarter. The position peaked at $290K in Q4 2016. 137 funds tracked by Wall St. Rank hold LXRX as of Q1 2017.

Glenmede Trust reported no remaining Lexicon Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Glenmede Trust sold 20,985 Lexicon Pharmaceuticals shares in Q1 2017, an estimated $290K.
Glenmede Trust first reported a position in Lexicon Pharmaceuticals in Q4 2016 and held it in 1 quarter.
Glenmede Trust's Lexicon Pharmaceuticals position peaked at $290K in Q4 2016.
137 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2017.

Based on Glenmede Trust's 13F filing for Q1 2017, filed 15 May 2017.